Fountain Valley, CALIFORNIA8 Active Studies

Lung Cancer Clinical Trials in Fountain Valley, CALIFORNIA

Find 8 actively recruiting lung cancer clinical trials in Fountain Valley, CALIFORNIA. Connect with local research sites and explore new treatment options.

8
Active Trials
4
Sponsors
3,787
Enrolling

Recruiting Lung Cancer Studies in Fountain Valley

RecruitingFountain Valley, CALIFORNIANCT05211895

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with du...

860 participants
AstraZeneca
View Study Details
RecruitingFountain Valley, CALIFORNIANCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy ...

675 participants
AstraZeneca
View Study Details
RecruitingFountain Valley, CALIFORNIANCT06564844

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgic...

660 participants
AstraZeneca
View Study Details
RecruitingFountain Valley, CALIFORNIANCT06417814

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS)....

630 participants
AstraZeneca
View Study Details
RecruitingFountain Valley, CALIFORNIANCT06350097

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy ...

582 participants
AstraZeneca
View Study Details
RecruitingFountain Valley, CALIFORNIANCT05468489

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Sub...

200 participants
Shanghai Henlius Biotech
View Study Details
RecruitingFountain Valley, CALIFORNIANCT05609578

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with a...

90 participants
Mirati Therapeutics Inc.
View Study Details
RecruitingFountain Valley, CALIFORNIANCT05456256

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this stu...

90 participants
Lantern Pharma Inc.
View Study Details

About Lung Cancer Clinical Trials in Fountain Valley

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 8 lung cancer clinical trials recruiting participants in Fountain Valley, CALIFORNIA. These studies are seeking a combined 3,787 participants. Research is being sponsored by AstraZeneca, Shanghai Henlius Biotech, Mirati Therapeutics Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Fountain Valley — FAQ

Are there lung cancer clinical trials in Fountain Valley?

Yes, there are 8 lung cancer clinical trials currently recruiting in Fountain Valley, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fountain Valley?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fountain Valley research site will contact you about next steps.

Are clinical trials in Fountain Valley free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fountain Valley studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 8 active trials in Fountain Valley are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov